

defensins and cancer

This manuscript ([permalink](#)) was automatically generated from [Jonzalez/rev@4f6e3d0](#) on May 7, 2020.

Authors

- **Jonathan Gonzalez**

 [XXXX-XXXX-XXXX-XXXX](#) ·  [jonzalez](#)

Department of Something, University of Whatever · Funded by Grant XXXXXXXX

- **None**

 [XXXX-XXXX-XXXX-XXXX](#)

Department of Something, University of Whatever; Department of Whatever, University of Something

Abstract

In humans, endogenous Antimicrobial peptides (AMP) are part of the immune system and act against pathogens. Defensins compose a class of AMPs that have activity against gram-positive and -negative bacteria and viruses. Their role in innate immunity as microbicidal and immunoregulatory agents that orchestrate cross-talk with the adaptive immune system, and, most recently, their association with cancer. Defensins produced by cells in the course of innate host defence serve as signals which initiate, mobilise, and amplify adaptive immune host defences. Linkage of defensins to weak tumour antigens potentiates their immunoadjuvant effects. Defensins use multiple cellular receptors, which endows them with the capacity to marshal adaptive host defences against microbial invaders. Recently, findings related to specific activation pathways of some of defensins have led investigators to associate them with pro-tumoral activity, contributing to a tumorigenic microenvironment. This review summarizes current knowledge of defensins to discuss their role in tumour growth, tumour monitoring and cancer treatment, is substantial interest in the identification of circulating human tumor-derived proteins in serum for the purposes of early cancer diagnosis.

Introduction

AMP have been isolated and characterized from a wide range of animal, plant and bacterial species and are known to play important roles in the host defence system and innate immunity [1](#)

(AMP) are polypeptides of fewer than 100 amino acids contain a positive net charge (from +2 to +9), high lysine and arginine content, and a significant number of hydrophobic residues ($\geq 30\%$) [2](#).

These properties permit the peptides to fold into amphipathic conformations upon contact with cell membranes, and the positively charged polar face help the molecules bind to the membrane through electrostatic interaction with the negatively charged head groups of phospholipids [3](#)

The history of AMPs dates back to 1922 with the discovery of lysozyme by Alexander Flemming. The first reported animal originated AMP is defensin, which was isolated from rabbit leukocytes in 1956 [4](#). at the same time, it was also proven that human leukocytes contain AMPs in their lysosomes.

for mammals, there are two main genetic categories for AMP, have been implicated in antimicrobial activity of phagocytes, inflammatory and epithelial secretions. Defensins are widely distributed in epithelial cells and phagocytes, [5](#). Cathelicidins are structurally and evolutionarily distinct antimicrobial peptides that are similar to defensins in abundance and distribution [6](#)

The great diversity of AMP differs from one animal species to another. In this review I will focus on defensins because, in a medical among all the antimicrobial peptides, defensins are particularly prominent in humans, as evidenced by the large number of expressed human genes [6](#), the various forms that are present in human tissues, and the ubiquitous occurrence of defensins in inflamed or infected human tissues [2](#).

Mammalian defensins are cationic AMP, with relatively arginine-rich nonglycosylated peptides with a molecular mass of 3.5–4.5 kDa. Their structure typically contains three intramolecular disulphide bridges between six cysteine residues [7](#). As mentioned for AMP in general, the classification of defensins is based on their structure, which divides them into three groups: α -defensins, β -defensins, and θ -defensins. In α -defensins, intramolecular bonding occurs between cysteines 1-6, 2-4, and [8](#), whereas in β -defensins it is between 1-5, 2-4, and 3-6 [9](#). Human defensins are produced in leukocytes and are also secreted by different epithelial cells and mucosal tissues. These human peptides have antimicrobial activity against a large number of gram-positive and -negative bacteria, fungi, and viruses [10](#). table 1

α -Defensins	sequence
HNP-1	ACYCRIPACIAGERRYGTCIYQGRLWAFCC
HNP-2	CYCRIPACIAGERRYGTCIYQGRLWAFCC
HNP-3	DCYCRIPACIAGERRYGTCIYQGRLWAFCC
HNP-4	VCSCRLVFCRRELRVGNCLIGGVSTFYCCTRVD
HNP-5	ATCYCRTGRCATRESLSGVCEISGRLYRLCCR
HNP-6	TCHCR-RSCYSTEYSYGTCTVMGINHRFCCL

β -defensins	sequence
hBD-1	GNFLTGLGHRSDHYN CVSSGGQCLYSACPIFTKIQGT CYRGKAKCCK
hBD-2	GIGDPVTCLKSGAICHPVFCPRRYKQIGT CGLPGTKCCKKP

β-defensins	sequence
hBD-3	GIINTLQKYYCVRGGRCAVLSCLPKEEQIGKCSTRGRKCCRRKK
hBD-4	EFELDRI CGYGTARCRK-KCRSQEYRIGRCPN-TYACCCLRKWDESLNRTKP

defensins

defensins 1

References

1. **Design of an α -helical antimicrobial peptide with improved cell-selective and potent anti-biofilm activity**

Shi-Kun Zhang, Jin-wen Song, Feng Gong, Su-Bo Li, Hong-Yu Chang, Hui-Min Xie, Hong-Wei Gao, Ying-Xia Tan, Shou-Ping Ji

Scientific Reports (2016-06-08) <https://doi.org/ggt4kh>

DOI: [10.1038/srep27394](https://doi.org/10.1038/srep27394) · PMID: [27271216](https://pubmed.ncbi.nlm.nih.gov/27271216/) · PMCID: [PMC4897634](https://pubmed.ncbi.nlm.nih.gov/PMC4897634/)

2. **Defensins: antimicrobial peptides of innate immunity**

Tomas Ganz

Nature Reviews Immunology (2003-09) <https://doi.org/cx6gzg>

DOI: [10.1038/nri1180](https://doi.org/10.1038/nri1180) · PMID: [12949495](https://pubmed.ncbi.nlm.nih.gov/12949495/)

3. **Animal antimicrobial peptides: an overview.**

D Andreu, L Rivas

Biopolymers (1998) <https://www.ncbi.nlm.nih.gov/pubmed/10333735>

DOI: [10.1002/\(sici\)1097-0282\(1998\)47:6<415::aid-bip2>3.0.co;2-d](https://doi.org/10.1002/(sici)1097-0282(1998)47:6<415::aid-bip2>3.0.co;2-d) · PMID: [10333735](https://pubmed.ncbi.nlm.nih.gov/10333735/)

4. **PHAGOCYTIN: A BACTERICIDAL SUBSTANCE FROM POLYMORPHONUCLEAR LEUCOCYTES**

James G. Hirsch

The Journal of Experimental Medicine (1956-05-01) <https://doi.org/dzvswf>

DOI: [10.1084/jem.103.5.589](https://doi.org/10.1084/jem.103.5.589) · PMID: [13319580](https://pubmed.ncbi.nlm.nih.gov/13319580/) · PMCID: [PMC2136631](https://pubmed.ncbi.nlm.nih.gov/PMC2136631/)

5. **Defensins. Natural peptide antibiotics of human neutrophils.**

T Ganz, ME Selsted, D Szklarek, SS Harwig, K Daher, DF Bainton, RI Lehrer

Journal of Clinical Investigation (1985-10-01) <https://doi.org/bb8wz4>

DOI: [10.1172/jci112120](https://doi.org/10.1172/jci112120) · PMID: [2997278](https://pubmed.ncbi.nlm.nih.gov/2997278/) · PMCID: [PMC424093](https://pubmed.ncbi.nlm.nih.gov/PMC424093/)

6. **Cathelicidins: a novel protein family with a common proregion and a variable C-terminal antimicrobial domain.**

M Zanetti, R Gennaro, D Romeo

FEBS letters (1995-10-23) <https://www.ncbi.nlm.nih.gov/pubmed/7589491>

DOI: [10.1016/0014-5793\(95\)01050-o](https://doi.org/10.1016/0014-5793(95)01050-o) · PMID: [7589491](https://pubmed.ncbi.nlm.nih.gov/7589491/)

7. **Mammalian defensins in the antimicrobial immune response**

Michael E Selsted, Andre J Ouellette

Nature Immunology (2005-05-19) <https://doi.org/bcth9d>

DOI: [10.1038/ni1206](https://doi.org/10.1038/ni1206) · PMID: [15908936](https://pubmed.ncbi.nlm.nih.gov/15908936/)

8. **Antimicrobial activity, mechanism of action, and methods for stabilisation of defensins as new therapeutic agents**

Meri Amerikova, Ivanka Pencheva El-Tibi, Vania Maslarska, Stanislav Bozhanov, Konstantin Tachkov

Biotechnology & Biotechnological Equipment (2019-05-11) <https://doi.org/ggt6q5>

DOI: [10.1080/13102818.2019.1611385](https://doi.org/10.1080/13102818.2019.1611385)

9. **Defensins and host defense.**

T Ganz

Science (New York, N.Y.) (1999-10-15) <https://www.ncbi.nlm.nih.gov/pubmed/10577203>

DOI: [10.1126/science.286.5439.420](https://doi.org/10.1126/science.286.5439.420) · PMID: [10577203](https://pubmed.ncbi.nlm.nih.gov/10577203/)

10. **Defensins: endogenous antibiotic peptides of animal cells.**

RI Lehrer, T Ganz, ME Selsted

Cell (1991-01-25) <https://www.ncbi.nlm.nih.gov/pubmed/1988144>

DOI: [10.1016/0092-8674\(91\)90632-9](https://doi.org/10.1016/0092-8674(91)90632-9) · PMID: [1988144](https://pubmed.ncbi.nlm.nih.gov/1988144/)